|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11-12
|
|
pubmed:dateCreated |
2001-6-21
|
|
pubmed:abstractText |
Palivizumab is approved in Switzerland for prevention of hospitalisation for RSV infection in children with one of the following risk factors: (1) history of prematurity < or = 35 weeks and age < or = 6 months or (2) chronic lung disease and age < or = 1 year. Regional data on the expected effectiveness of this monoclonal antibody are not available.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1424-7860
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
24
|
|
pubmed:volume |
131
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
146-51
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11416887-Antibodies, Monoclonal,
pubmed-meshheading:11416887-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:11416887-Antiviral Agents,
pubmed-meshheading:11416887-Cost-Benefit Analysis,
pubmed-meshheading:11416887-Female,
pubmed-meshheading:11416887-Hospitalization,
pubmed-meshheading:11416887-Humans,
pubmed-meshheading:11416887-Infant,
pubmed-meshheading:11416887-Infant, Newborn,
pubmed-meshheading:11416887-Infant, Premature,
pubmed-meshheading:11416887-Male,
pubmed-meshheading:11416887-Respiratory Syncytial Virus Infections,
pubmed-meshheading:11416887-Retrospective Studies,
pubmed-meshheading:11416887-Risk Factors,
pubmed-meshheading:11416887-Statistics, Nonparametric,
pubmed-meshheading:11416887-Switzerland,
pubmed-meshheading:11416887-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants.
|
|
pubmed:affiliation |
Department of Paediatrics and Institute for Infectious Diseases, University of Bern, Switzerland.
|
|
pubmed:publicationType |
Journal Article
|
